Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | HPGD | P15428 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | RECQL | P46063 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | APEX1 | P27695 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1412334 | 0.99 | ALDH1A1 (0.97) | ALDH1A1MAPTHPGDSMN1; SMN2NPC1 | |
| SCHEMBL16921246 | 0.85 | ALDH1A1 (1.00) | ALDH1A1MAPTHPGDSMN1; SMN2NPC1 | |
| SCHEMBL1412471 | 0.85 | ALDH1A1 (0.74) | ALDH1A1MAPTHPGDSMN1; SMN2NPC1 | |
| SCHEMBL2017324 | 0.85 | ALDH1A1 (1.00) | ALDH1A1MAPTHPGDSMN1; SMN2NPC1 | |
| SCHEMBL2020656 | 0.83 | ALDH1A1 (1.00) | ALDH1A1MAPTHPGDSMN1; SMN2NPC1 | |
| SCHEMBL1412333 | 0.83 | ALDH1A1 (0.71) | ALDH1A1MAPTHPGDSMN1; SMN2NPC1 | |
| SCHEMBL13096450 | 0.82 | ALDH1A1 (0.69) | ALDH1A1MAPTHPGDSMN1; SMN2NPC1 | |
| SCHEMBL1412273 | 0.82 | ALDH1A1 (0.69) | ALDH1A1MAPTHPGDSMN1; SMN2NPC1 | |
| SCHEMBL2017456 | 0.81 | MAPT (0.75) | ALDH1A1MAPTHPGDSMN1; SMN2NPC1 | |
| SCHEMBL1412284 | 0.80 | MAPT (0.67) | ALDH1A1MAPTHPGDSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150202195-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2015-07-23 | — | — | US | claimed |
| US-9029376-B2 | Small molecule inhibitors for the treatment or prevention of dengue virus infection | SIGA TECHNOLOGIES, INC. (US) | 2015-05-12 | — | — | US | claimed |
| US-20110158940-A1 | SAMLL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-06-30 | — | — | US | claimed |
| EP-2293671-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | Siga Technologies, Inc. (US) | 2011-03-16 | — | — | EP | claimed |
| WO-2009149054-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2009-12-10 | — | — | WO | claimed |
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-20150202195-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150202195-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150202195-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-9029376-B2 | Small molecule inhibitors for the treatment or prevention of dengue virus infection | SIGA TECHNOLOGIES, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029376-B2 | Small molecule inhibitors for the treatment or prevention of dengue virus infection | SIGA TECHNOLOGIES, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029376-B2 | Small molecule inhibitors for the treatment or prevention of dengue virus infection | SIGA TECHNOLOGIES, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20110158940-A1 | SAMLL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110158940-A1 | SAMLL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-06-30 | — | — | US | disclosed |
| EP-2293671-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | Siga Technologies, Inc. (US) | 2011-03-16 | — | — | EP | disclosed |
| WO-2009149054-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009149054-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202195-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SNRPE, EIF2AK2, HAVCR2 | ALDH1A1 3106/4885MAPT 219/4885HPGD 2186/4885 |
| US-20110158940-A1 | SAMLL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | HAVCR2, HNRNPLL, SAMSN1 | ALDH1A1 2694/4885MAPT 480/4885HPGD 2847/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | ALDH1A1 1652/4885MAPT 4858/4885HPGD 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.